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Abstract
Congenital heart diseases (CHD) represent the most common birth defect in human. The majority of cases are
caused by a combination of complex genetic alterations and environmental influences. In the past, many disease-
causing mutations have been identified; however, there is still a large proportion of cardiac malformations with
unknown precise origin. High-throughput sequencing technologies established during the last years offer novel
opportunities to further study the genetic background underlying the disease. In this review, we provide a roadmap
for designing and analyzing high-throughput sequencing studies focused on CHD, but also with general applicability
to other complex diseases. The three main next-generation sequencing (NGS) platforms including their particular
advantages and disadvantages are presented.To identify potentially disease-related genomic variations and genes, dif-
ferent filtering steps and gene prioritization strategies are discussed. In addition, available control datasets based
on NGS are summarized. Finally, we provide an overview of current studies already using NGS technologies and
showing that these techniques will help to further unravel the complex genetics underlying CHD.
Keywords: next-generation sequencing; congenital heart disease; sequence variations; variation filtering; whole-exome data-
sets; genomics
INTRODUCTION
Over the last years, the application of automated
Sanger sequencing and microarrays for genomic
and genetic analyses has been increasingly replaced
by next-generation sequencing (NGS) technologies.
These high-throughput technologies are able to gen-
erate far more sequence data, in less time and with
lower costs. This adds a particular advantage to many
non-Mendelian diseases with a clear genetic compo-
nent, where it has been a great challenge to identify
the contributions made by single or even multiple
genes. Doing so might permit the establishment of a
profile for the disease that could be used for diagnos-
tic purposes as well as predicting the likely outcome
of particular therapeutic interventions. Using NGS,
previously inaccessible insights into cognitive and
neurological disorders, schizophrenia, cancer and
cardiovascular diseases have been gained [1–5] and
its application in clinical settings is increasingly
being explored [6–9]. These technologies also open
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new opportunities for the study of cardiovascular
development and complex human disorders like
congenital heart disease (CHD). Here, we give an
overview about the latest NGS technologies and
provide a roadmap for study design and analysis of
genomic CHD data. Furthermore, available control
datasets and studies using NGS to investigate the
genetics of congenital heart malformations are
summarized.
CHD are the most common birth defect in
human with an incidence of 1% in all live births
[10, 11]. For the United States it is estimated that
760 000 individuals with CHD born in 1990 or
later will be alive by the year 2020 [12]. In
Germany, a prevalence of 280 000 individuals
with CHD in 2020 is expected [13]. CHD comprise
a heterogeneous group of cardiac malformations that
arise during heart development and the long-term
clinical outcome after corrective surgery or interven-
tion varies depending on the malformation as well as
associated non-cardiac abnormalities [14]. Already
decades ago, a multifactorial background of CHD
with genetic–environmental interactions has been
assumed [15]. A number of environmental influences
during pregnancy are well-known to increase the
risk of CHD, such as alcohol, teratogens and infec-
tious agents [16–18] as well as common diseases like
obesity and diabetes [19, 20]. Approximately 30% of
cardiac malformations are part of syndromic disorders
like Down syndrome, 22q11.2 deletion syndrome
and Holt–Oram syndrome [21–23]; however, the
majority of CHD occurs sporadically and does not
follow Mendelian inheritance [15].
In the last decades studying familial cases using
classical linkage analyses or performing candidate
gene approaches based on knowledge gained in
model organisms such as knockout mice have
helped to gather major insights into the genetic
background of CHD. Examples are families with
atrial septal defect and conduction delay harboring
mutations in the homeobox transcription factor
NKX2-5 [24], or a large family suffering from iso-
lated septal defects related to a missense mutation in
the transcription factor GATA4 [25]. Based on
knockout mouse data, the gene CITED2 was ana-
lyzed using denaturing high-performance liquid
chromatography (DHPLC) and direct sequencing,
resulting in the identification of mutations in patients
with different types of cardiac malformations [26].
Chromosomal aberrations including copy number
variations (CNVs) can be identified by cytogenetic
analysis including fluorescent in situ hybridization
(FISH). For example, the majority of DiGeorge syn-
drome cases are caused by a chromosomal microde-
letion (22q11) [27, 28]. However, some of the
patients lack this deletion but harbor mutations in
the T-box gene TBX1 located in 22q11, displaying
its important role for CHD [29]. Array comparative
genomic hybridization (array CGH) offers a higher
resolution for screening of submicroscopic chromo-
somal imbalances. The first studies using array CGH
showed that 17% of CHD patients harbor poten-
tially disease-causing rare chromosomal aberrations
[30, 31]. More recently, genome-wide SNP arrays
[32] were used to identify copy number changes in
sporadic CHD [33, 34]. To find single nucleotide
polymorphisms (SNPs) associated with complex dis-
orders, genome-wide association studies (GWAS)
have been performed in large cohorts comprising
hundreds to thousands of individuals [35]. The first
studies on CHD identified loci associated with the
risk of Tetralogy of Fallot (TOF) and septation
defects [36–38].
Taken together, these studies have provided valu-
able insights into the genetics of CHD, as reviewed
elsewhere [39–41]. However, there is still a large
proportion of cardiac malformations for which no
underlying cause could be identified. NGS tech-
niques now provide a powerful novel approach to
further elucidate the genetic background of CHD.
They allow the simultaneous analysis of thousands of
genes or even the whole genome in large patient
cohorts. In contrast to microarrays, they are not de-
pendent on DNA hybridization to preselected
probes, which facilitates the identification of novel
variations at a single-base resolution without a priori
sequence information. Thus, they will enable the
discovery of novel disease genes and networks.
Nevertheless, the identification of true disease-
related genes is complicated by the huge amount
of data that is generated. Large-scale population stu-
dies showed that a high number of potentially patho-
genic variations can be observed in any healthy
individual [42–44], with >95% being rare [42].
Using NGS, some variations identified to be disease
causing in the past based on their exclusive occur-
rence in patients are now also found, albeit at very
low frequencies, in healthy individuals and seem to
be tolerated in the individual context. Thus, the ap-
plication of novel sequencing approaches to the ana-
lysis of complex disorders like CHD remains
challenging.













The current high-throughput sequencing technolo-
gies offer a variety of different study designs, which
have to be considered carefully with regard to the
scientific question being asked. The number of indi-
viduals selected for sequencing, the pooling of sam-
ples (multiplexing), the number of selected target
bases, the choice of the sequencing platform as
well as the desired read depth and length determine
the costs and the major bottlenecks for research
projects.
One important aspect of study design is the selec-
tion of individuals for sequencing. Depending on the
research question, the availability of samples and
costs, one might focus on families (e.g. trios), unre-
lated individuals or cases with extreme phenotypes.
For small cohorts, the selection of well-defined,
homogenous (sub)phenotypes can increase the sig-
nificance of the study, as has been shown for apical
hypertrophic cardiomyopathy [45]. However, large
consortia now enable the analysis of hundreds of pa-
tients, which represent diverse CHD phenotypes.
Using barcodes for multiplexing allows the simultan-
eous sequencing of a larger number of samples and
thus reduces the time and costs for data generation
when analyzing large cohorts.
Another crucial step is the choice between
whole-genome sequencing (WGS), whole-exome
sequencing and targeted resequencing. They all
have their individual strengths and limitations and
are suitable for different scientific questions. WGS
allows gaining a broad understanding of the full
range of genomic variations including e.g. enhancers
and promoters. However, due to high costs and time
needed to achieve an adequate read depth, WGS is
not feasible for many studies. Thus, whole-exome
and targeted resequencing approaches have been es-
tablished as an alternative. Whole-exome sequencing
enables the sequencing of almost all protein-coding
regions, often combined with a high coverage. For
rare inherited disorders, it has been shown that focus-
ing on the exome is reasonable because the majority
of mutations responsible for Mendelian diseases affect
protein-coding sequences [46]. If knowledge about
possible candidate genes and disease pathways is al-
ready available, the targeted resequencing of selected
regions is a promising option. To select genomic
regions for targeted resequencing, data from previous
projects like sequencing analyses, GWAS studies,
animal models as well as publicly available databases
and other web resources can be used. In addition,
gene prioritization tools can be employed to narrow
down the list of genes of interest [47, 48], which
enables their analysis in a much larger cohort of pa-
tients and controls. For CHD, the CHDWiki offers a
repository of current knowledge on the genetic basis
of the disease [49]. However, due to the constantly
decreasing sequencing costs, whole-exome sequen-
cing should be applied if possible, because it is not
limited to the selection of genes. Thus, the more
comprehensive data allow the discovery of novel dis-
ease pathways and can be used for subsequent pro-
jects. Both exome and targeted resequencing require
sequence enrichment technologies like array-based
sequence capturing. Care should be taken when
comparing different datasets, because the use of dif-
ferent enrichment techniques can lead to differences
in the captured regions ranging from whole genes
down to single bases.
In addition to identifying the genomic positions
and nucleotide changes of a wide range of alter-
ations, recent advances in sequencing technologies
also enable the independent determination of both
haplotype sequences of individual genomes. This
phase information, i.e. the separation of maternally
and paternally derived sequences, are important for
understanding gene function and disease [50]. The
successful application of this approach has been
demonstrated in several studies [51–53]. It allows
the discrimination of cis and trans configurations of
mutations and can provide valuable insights into dis-
ease mechanisms like compound heterozygosity.
Next-generation sequencing platforms
Once a decision about the samples and genomic re-
gions to be sequenced has been made, the next step
is to select a sequencing platform. NGS technologies
are evolving rapidly and during the last years several
platforms were released. Although they differ in their
biochemistry, all follow the principle of cyclic-array
sequencing, where an array of DNA features is itera-
tively enzymatically sequenced combined with
imaging-based data detection [54].
Recently, the HiSeq 2000/2500 instrument
(Illumina), GS FLXþ system (Roche/454) and
SOLiD 5500/5500xl Wildfire system (Life Technol-
ogies) have set the standard for high-throughput
sequencing. There are differences between these
platforms resulting in specific advantages and disad-
vantages (Figure 1), which also have to be taken into
account when comparing different datasets. In add-
ition to the standard high-throughput sequencing












platforms, three benchtop platforms have been
released, envisaged for smaller laboratories and the
clinical diagnostic market [55]. The MiSeq (Illu-
mina), 454 GS Junior (Roche/454) and Ion Torrent
PGM/Ion Proton (Life Technologies) are lower
throughput fast-turnaround instruments, which
need much less instrument space and offer less set-
up [55, 56].
Figure 1: NGS platforms. Overview of the three most common high-throughput sequencing platforms currently
available. The information provided are based on company sources alone. B, Billion; bp, base pairs; hrs, hours; Gb,
Giga bases; Mb, Mega bases; nt, nucleotides; PCR, polymerase chain reaction. *Illumina HiSeq 2500 only.












In general, a higher number of sequence reads
from NGS results in greater sequencing depth and
thus in higher sequence confidence. For example,
the different phases within the 1000 Genomes Pro-
jects range from low coverage (2–6) for whole-
genome sequence data to high coverage (50–100)
for exome sequence data [57]. Moreover, the overall
accuracy and specific error distribution (e.g. ten-
dency for systematic errors) of the different technol-
ogies have to be considered [54].
IDENTIFICATIONOF GENOMIC
VARIATIONS
Single nucleotide variations (SNVs) represent the
most abundant type of genomic variation, followed
by short (<50 bases) insertions and deletions
(InDels), summarized as local variations. Common
SNVs (SNPs) occur in >1% of a population.
InDels are both less frequent and subjected to a
stronger purifying selection compared with SNVs
because they create larger changes in coding regions
such as frameshifts and insertions/deletions of amino
acids. In contrast, SNVs often produce synonymous
changes with less or no impact on gene function
[58].
After sequencing, the first preprocessing step is the
quality assessment of the raw sequence reads. Several
tools are available for this purpose, including FastQC
(http://www.bioinformatics.babraham.ac.uk/projec
ts/fastqc/), FASTX-Toolkit (http://hannonlab.cshl.
edu/fastx_toolkit/) and NGS QC Toolkit (http://
www.nipgr.res.in/ngsqctoolkit.html) [59], which all
can also be used for the handling of NGS data in
general.
The method of choice for the identification of
local variations is the mapping of sequence reads to
a known reference genome (alignment-consensus
approach). Many algorithms have been developed
specifically for this purpose (e.g. Bowtie 2, BWA,
RazerS 3, SOAP3 [60–63]), which has been re-
viewed elsewhere [64].
After taking sequencing and alignment problems
into account (e.g. using the GATK realignment
[65]), several SNV and InDel calling tools can be
used, such as mpileup (samtools), GATK,
VarScan2, SOAPsnp, SOAPindel and Pindel
[65–71], as reviewed elsewhere [72, 73]. From the
computational perspective, algorithms for the detec-
tion of SNVs are much more advanced than for the
detection of InDels, partially due to the difficulties of
detecting InDels in relatively short sequence reads.
However, having long reads from NGS does not
necessarily help to find true InDels. The platform
from Roche/454 produces reads with a length of
up to 1000 bp (Figure 1) but tends to identify
many false InDels because of its problem to correctly
assess the length of homopolymer repeats, resulting
in over- and undercalls [74].
CNVs are much larger genetic alterations (up to
millions of DNA bases). There are four main com-
putational methods for detecting copy numbers from
NGS data, namely read-depth, read-pair, split-read
and assembly-based methods. Assembly-based
approaches perform best for smaller genomes and
are less widely used for the human genome because
the assembly in repeat regions is difficult with short
read lengths [75]. Split-read methods (e.g. Pindel
[71]) can detect deletions and small insertions at
single base pair resolution, thus defining the exact
breakpoint [32]. They were first applied to longer
reads from Sanger sequencing [76] and they are cur-
rently used to identify rearrangement points in the
long sequence reads from Roche/454 (Roche GS
Reference Mapper). Read-pair approaches (e.g.
PEMer, BreakDancer, VariationHunter [77–79])
consider the span and orientation between two
pairs of reads (paired-end) [32] but they are limited
by the insert size when detecting insertions (see ‘Pros
and Cons’ in Figure 1) [80]. Read-depth methods
(e.g. mrCaNaVar and CNVnator [81, 82]) assume
that the mapped reads are randomly distributed
across the reference genome or targeted regions.
They investigate differences from the expected read
distribution to detect duplications (higher read
depth) and deletions (reduced read depth) [32].
IDENTIFICATIONOF CANDIDATE
GENES
Genes affected by raw local variations must be
reduced to potential disease-causing genes, which
are candidates for further downstream analyses.
This includes the filtering of all local variations for
functional relevance and frequency in control data-
sets as well as the gene prioritization process and the
validation of related variations.
Filtering of local variations
Variation calling often results in false positives and
negatives resulting from technical bias (duplicate
reads, strand and GC bias), sequencing errors












(e.g. increased error probability at the 30-end of
Illumina reads and at homopolymer repeats in
Roche/454 sequencing) and alignment artifacts in
low mappability regions [32]. The variation calling
methods already try to minimize the number of false
positives. However, to further reduce these errors
and to identify functionally relevant variations add-
itional filtering steps have to be applied.
First, variations should be filtered by the sequen-
cing quality including the read depth (coverage),
number of supporting reads, average base quality
(e.g. Phred score 20), supporting strands (i.e. for-
ward and/or reverse) and variation allele frequency
(step 1 in Figure 3). Variations with an allele fre-
quency <0.2 should be discarded, while frequencies
between 0.2 and 0.8 are called heterozygous and
those >0.8 are considered as homozygous [83].
Moreover, variations with an excessively high cover-
age are usually caused by structural variations like
CNVs or other alignment artifacts.
The next filtering step is the annotation and func-
tional characterization of the variations (step 2 in
Figure 3). Several tools are available to annotate vari-
ations from NGS data such as SeattleSeq (http://snp.
gs.washington.edu/SeattleSeqAnnotation/), ANOVA,
VAT, F-SNP and snpEff [84–87]. To identify
putatively deleterious SNVs, functional prediction
methods (e.g. PolyPhen-2, SIFT, MutationTaster
and a likelihood ratio test [88–91]) and conserva-
tion-based methods (e.g. PhastCons, GERPþþ,
PhyloP, SCONE [92–95]) can be applied. Using mul-
tiple methods can help to obtain more reliable func-
tional predictions and thus, to focus on the most likely
relevant variations [96]. Over all, variations not pre-
dicted to be damaging, nonsense, frame-shifting or
inserting/deleting amino acids as well as variations
not affecting splice sites, non-coding RNAs (e.g.
seeds of microRNAs) or other regulatory regions
(e.g. promoter or enhancer) might be discarded. An
overview of the different types of genomic annota-
tions and functional characterizations of local vari-
ations is given in Figure 2.
The retained variations can subsequently be
reduced to novel variations or rare variations with
a minor allele frequency (MAF) of 0.01 in the
dbSNP database [97] or other public datasets,
which will be presented in the next section. Rare
and de novo mutations are the main genetic cause for
CHD and thus, filtering for rare variations or vari-
ations not present in dbSNP can reduce the search
space by 2 - to 10-fold while retaining the most
promising candidates. However, known disease-
associated variations present for example in the
OMIM, KEGG disease, HGMD and ClinVar data-
base [98–102] or the CHDWiki [49] might be
retained (step 3 in Figure 3).
AVAILABLE CONTROLDATASETS
Several datasets and databases are available that can be
used to filter for rare variations (step 3 in Figure 3).
To catalog short genomic variations dbSNP was es-
tablished [97]. The database summarizes data from
various projects using different genotyping methods.
Examples for contributing large-scale projects are the
HapMap Project, the 1000 Genomes Project and the
ClinSeq Study (CSAgilent) [57, 103–105]. Of
course, dbSNP is not always complete and accurate,
as it contains false positives and might be contami-
nated by single nucleotide differences arising from
paralogous sequences in the genome [106, 107].
As an alternative or in addition to dbSNP, separ-
ate datasets can also be used as controls. Currently,
several NGS datasets of large cohorts are being gen-
erated and are already partly available. The 1000
Genomes Project aims to sequence the genomes of
2500 individuals of European, East Asian, West
African, American and South Asian ancestry using a
combination of low-coverage WGS (2–6), tar-
geted deep exome sequencing (50–100) and
dense SNP genotyping [57, 104]. The Exome
Sequencing Project of the National Heart, Lung
and Blood Institute (NHLBI) provides whole-
exome sequencing data of 6503 individuals from
multiple cohorts to study heart, lung and blood dis-
orders [42, 96]. The ClinSeq Study focuses on car-
diovascular health and aims to recruit >1500
participants. A total of 662 participants of European
descent have already undergone whole-exome
sequencing and the data are publicly available
[9, 105].
Li and colleagues analyzed 200 healthy Danish
individuals by whole-exome sequencing at low
coverage. This dataset also contains individual geno-
types in addition to the accumulated frequency for
each variation [44]. The project ‘Genome of the
Netherlands’ (GoNL) aims to capture the genetic
variation present in the Dutch population and has
performed WGS of 769 individuals belonging to
250 families with two parents and one or two chil-
dren [108].












The UK10K project is currently performing
WGS for 4000 individuals (including twin pairs)
and whole-exome sequencing for 6000 individuals
showing disease phenotypes in the three large groups
obesity, neurodevelopmental disorders and rare dis-
eases including 125 CHD cases. The sequencing data
are already partly available through the European
Genome-phenome Archive (EGA; https://www.
ebi.ac.uk/ega/) at the EBI. In general, NGS datasets
can also be obtained from the database of Genotypes
and Phenotypes (dbGaP; http://www.ncbi.nlm.nih.
gov/gap) [109] at the NCBI. A summary of the
described datasets is given in Table 1. When analyz-
ing trio samples or larger families, a further oppor-
tunity is to use healthy family members as additional
controls and to filter for de novo mutations, which
will be discussed in the following section.
In general, the selection of a suitable control data-
set mainly depends on the technical comparability
and the individuals selected for sequencing. The
control and the study cohort should preferably be
enriched with the same technique and sequenced
with the same platform. Moreover, the control in-
dividuals should belong to the same ethnical group as
the studied cases and phenotypic information of the
controls should also be considered. For example, the
individuals sequenced within the NHLBI project
belong to multiple disease groups like atherosclerosis,
asthma and cystic fibrosis.
Gene prioritization
After filtering for rare deleterious variations using
prediction tools and control datasets, the resulting
affected genes can be prioritized to identify the
most likely disease-related genes and to further
reduce the number of candidate genes for down-
stream studies (step 4 in Figure 3).
Automated gene prioritization approaches require
prior knowledge about the disease and associated
genes and pathways. They integrate diverse data
including protein–protein interactions, animal
models, coexpression, gene ontologies (e.g. GO
[110]), sequence homologies and literature co-oc-
currences and include tools like GeneSeeker and
Endeavour [111, 112]. They can link the candidate
genes to known disease-associated genes and gener-
ate a ranked list, with the most promising candidates
at the top [47, 48].
Pathway databases and analysis tools, which can
also be used for the gene prioritization process by
Figure 2: Genomic annotations and functional characterizations of local variations.The main functionally relevant
types of variations are marked in bold. UTR, untranslated region.












Figure 3: Identification of candidate genes. The individual filtering steps from raw local variations to potential dis-
ease-related variations and genes are shown including different data sources, tools and approaches that can be used.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































placing candidate genes into the context of knownmo-
lecular pathways, include KEGG, STRING,
HumanNet, FunCoup, Reactome [99, 100, 113–116]
or the commercial Ingenuity Pathway Analysis (IPA;
www.ingenuity.com/). For Mendelian diseases the
human gene connectome (HGC) approach was re-
cently introduced [117].
Since CHD is a developmental disorder, the genes
causing it must be functional during heart develop-
ment. Moreover, the gene expression in adult heart
might be important regarding the long-term clinical
outcome. Thus, cardiac expression might be used as a
further criterion for prioritizing candidate genes.
Expression can be measured by e.g. quantitative
PCR, serial analysis of gene expression (SAGE), ex-
pression array or RNA-seq, which was recently used
in a high-throughput screen of CHD candidate
genes [118]. Already published data can be retrieved
from e.g. Mouse Atlas, ArrayExpress, Bgee and GEO
[119–122]. For individual genes, literature research
for expression data can be guided by e.g. MGI
(Mouse Genome Informatics; http://www.inform-
atics.jax.org/). Moreover, spatial mouse expression
data based on in situ hybridization can be obtained
from the EMAGE, Genepaint and Eurexpress data-
bases [123–125].
When analyzing family trios, one approach is to
further filter for genes with denovo mutations, assum-
ing that a unique mutation is causing CHD in the
offspring [118]. In addition, large CHD pedigrees
offer the opportunity to analyze Mendelian inherit-
ance of disease-causing mutations. Another approach
is to consider the combination of variations in dif-
ferent genes and the mutation frequencies of the
genes, assuming an oligo- or multigenic background
with disease-related genes more often affected by
deleterious mutations in cases compared to controls.
Validation of NGS results
Today’s NGS platforms generate highly accurate
data, as shown by validation studies using Sanger
sequencing. When using a high coverage threshold
for variation calling (30), 100% of variations
can be confirmed [126, 127]. However, when select-
ing for rare variations overrepresented in a cohort,
one also runs the risk of enriching false-positive vari-
ations that result from characteristic sequence fea-
tures or mapping problems at a specific position
and thus are likely to occur in several individuals.
In a study on TOF patients, 35 variations in 20
genes with a significantly higher mutation frequency
in cases compared with controls were initially iden-
tified. Four of these variations were found in mul-
tiple patients. Using Sanger sequencing, seven
variations (20%) could not be validated, including
the four variations that were detected in more than
one patient. Nevertheless, comparison to related
RNA-seq data showed that 94% of variations cov-
ered at least 10 could be confirmed and thus
demonstrated a high sequencing quality (unpub-
lished data). Notably, true-positive variations could
still be missed by RNA-seq due to allelic expression,
which is a widespread phenomenon that can be
mediated through mechanisms like alternative
mRNA processing or differential transcription
factor binding [128–130]. Taken together, validation
of variations detected by NGS sequencing should
additionally be performed as one of the last filtering
steps (step 5 in Figure 3).
HIGH-THROUGHPUT
SEQUENCING STUDIES ONCHD
To date, only few CHD studies based on NGS have
been published. One combined approach of whole-
exome sequencing, high-resolution melting analysis
and direct DNA sequencing of selected genes iden-
tified possible disease-causing mutations in a family
with heterogeneous CHD [131]. Whole-exome
sequencing of one heterotaxy patient with CHD
could identify a recessive missense mutation in
SHROOM3. Subsequent screening of 96 heterotaxy
patients using Sanger sequencing identified four add-
itional cases with rare variants in the gene, suggesting
a role of SHROOM3 in left–right patterning [132].
Another application of NGS identified a dominant
missense mutation causing the rare Cantu´ syndrome,
which includes cardiac manifestations. Here, whole-
exome sequencing of the index patient and his un-
affected parents was performed, identifying a single
de novo missense mutation in the potassium channel
gene ABCC9. Subsequently, missense mutations in
the ABCC9 gene could be detected in 13 of 15 add-
itional cases and functional studies showed that the
mutations lead to dominant channel opening [133].
Studying large cohorts of CHD patients using
high-throughput sequencing will hopefully lead to a
better understanding of the complex genetics under-
lying the disease. One example is the Congenital
Heart Disease Genetic Network Study established
by the Pediatric Cardiac Genomics Consortium,
which enrolled >3700 patients representing a diverse












range of congenital heart defects. The study aims to
investigate the relationships between genetic factors,
clinical features and outcomes in CHD patients. Med-
ical data and biospecimen were collected and ongoing
studies include the identification of CNVs, the
resequencing of candidate genes as well as the search
for somatic mutations and skewed allelic expression
using whole-exome sequencing and RNA sequen-
cing, respectively, from cardiac tissue samples [134].
For a subset of 362 patients and their parents whole-
exome sequencing from venous blood DNA has al-
ready been completed. Most interestingly, this study
revealed an accumulation of denovo mutations in his-
tone-modifying genes in CHD cases, underlining the
important role of epigenetic regulation in heart
development [118].
Another large-scale project is the Deciphering
Developmental Disorders (DDD) study (http://
www.ddduk.org/) headed by the Wellcome Trust
Sanger Institute, which aims to collect clinical data
and DNA samples from 12 000 undiagnosed children
with developmental disorders and their parents.
The study also includes CHD patients and uses
high-resolution array CGH, SNP genotyping, and
whole-exome sequencing to identify the genetic
causes underlying the diverse disorders [135].
Finally, the UK10K project (http://www.uk10k.
org/) is performing whole-exome sequencing for
125 CHD patients enclosed in its rare disease
sample set. Both studies are still ongoing and so far,
no results on CHD have been published.
CONCLUDING REMARKSAND
FUTURE PERSPECTIVES
The heart is the first organ that functions during
embryonic development, and congenital cardiac
malformation are the most common birth defect in
human. CHDs represent a heterogeneous group of
disorders with a complex genetic background.
Although many disease-causing genetic alterations
have been identified, there is still a large proportion
of CHD with unknown precise origin. During the
last years, high-throughput sequencing technologies
were established, which are still rapidly developing.
These NGS techniques offer novel opportunities to
further study the genetics underlying congenital
heart malformations. Furthermore, high-throughput
sequencing as well as many of the tools and databases
described here can also be applied to a wide range of
other complex diseases.
Besides the analysis of genomic variations, NGS
can be used for studying genetic and epigenetic al-
terations such as RNA and small RNA expression,
alternative splicing, DNA methylation and protein–
DNA interactions. Individual NGS datasets can al-
ready provide a wealth of information. However, the
combination of genomic, genetic and epigenetic as
well as proteomic and metabolic data in a systems
biology approach enables a more comprehensive
understanding of disease processes [136–138]. Just
recently, exome sequencing data of CHD patients
were linked to gene expression data from mouse to
filter for potentially disease-causing mutations [118].
Moreover, considering sequence variations in
regulatory regions like enhancers or promoters can
lead to valuable insights into regulatory changes
underlying a disease. These variations might disrupt
the assembly of the transcription machinery or
change transcription factor binding affinities [139].
Combining such findings with corresponding ex-
pression data can show the functional consequences
of observed variations. To date, several computa-
tional and experimental tools are available to assess
the pathogenicity of variations in regulatory elements
and numerous examples for disease associations have
been identified [140]. In a patient suffering from
ventricular septal defect, a homozygous variation in
the TBX5 enhancer could be shown to abrogate the
gene’s expression in the heart [141].
To analyze the effect of individual mutations in
combination with the complex genetic background,
the differentiation of patient-specific induced pluri-
potent stem cells might be a valuable approach. This
strategy was used to model several cardiac pheno-
types [142–144] and can prospectively be used for
drug discovery and development [145]. Hopefully, a
better understanding of the causes underlying cardiac
malformation will enable the development of novel
therapeutic and preventive strategies in the future.
Key points
 NGS technologies offer novel opportunities to study complex
genetic disorders like congenital heart disease.
 The huge amount of data generated with high-throughput
sequencing requires a sophisticated study design and analysis to
identify potentially disease-related variations and genes.
 There are several large-scale projects providing sequence infor-
mation for control cohorts comprising hundreds to thousands
of individuals.
 Current studies already using NGS technologies were able to
gain new insights into the genetic background of CHD.
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